Skip to main content

Genitourinary Syndrome of Menopause (GSM)

Genitourinary syndrome of menopause (GSM) is a chronic, progressive condition resulting from declining estrogen and androgen levels during the menopausal transition, affecting the vulva, vagina, urethra, and bladder. It affects approximately 27–84% of postmenopausal women and is widely underdiagnosed and undertreated.[1][2][3] The term was introduced in 2014 by the International Society for the Study of Women's Sexual Health and the North American Menopause Society to replace the narrower term "vulvovaginal atrophy."[4] For urogynecologists and pelvic reconstructive surgeons, GSM is a foundational diagnosis — urinary symptoms attributed to recurrent UTI, urgency incontinence, or bladder dysfunction may in fact represent genitourinary atrophy, and local estrogen therapy can be a first-line surgical adjunct before and after pelvic floor procedures.

Definition and terminology​

GSM encompasses the full constellation of genital, sexual, and urinary symptoms associated with hypoestrogenism — not limited to vaginal atrophy alone. Unlike vasomotor symptoms, which may resolve over time, GSM symptoms are typically progressive and unlikely to resolve spontaneously without treatment.[5][2]

GSM also occurs in premenopausal hypoestrogenic states, including postpartum and lactation, hypothalamic amenorrhea, and use of antiestrogenic medications such as aromatase inhibitors, GnRH agonists, and tamoxifen.[6][4]

Pathophysiology​

The underlying mechanism is estrogen deficiency leading to anatomic and physiologic changes throughout the genitourinary tract:[6][7][9]

  • Vaginal epithelium becomes thin, pale, and less elastic, with decreased perfusion and loss of rugae.
  • Vaginal pH rises above 4.5 (from the normal premenopausal range of 3.5–4.5), creating an environment less hospitable to Lactobacillus species.
  • Vaginal microbiome shifts from Lactobacillus-dominant communities to diverse anaerobic flora. Postmenopausal women have low-Lactobacillus communities at approximately 50% of visits, compared with ~21% in premenopausal women. Lactobacillus-dominated communities are associated with lower odds of vaginal atrophy and dryness.[8][9]
  • Urethral and bladder epithelium contain estrogen receptors and undergo atrophic changes, contributing to urinary frequency, urgency, dysuria, and recurrent UTI.[10]
  • Estrogen receptors (ERα and ERβ) are present throughout the vagina, urethra, bladder trigone, and pelvic floor musculature, explaining the broad symptom profile.[7][9]

Clinical presentation​

Symptoms span three domains:[6][4][2]

  • Genital: vaginal dryness, burning, itching, irritation, vaginal discharge, introital narrowing
  • Sexual: dyspareunia, decreased lubrication, post-coital bleeding
  • Urinary: urgency, frequency, dysuria, nocturia, recurrent urinary tract infections

Patients often do not volunteer these symptoms spontaneously; proactive screening is recommended at clinical encounters.[6][1]

Diagnosis​

Diagnosis is clinical, based on symptoms with or without physical findings, after ruling out other etiologies.[6][10]

  • Examination findings: thin, pale, or erythematous vulvar/vaginal epithelium; loss of rugae; introital narrowing; decreased tissue elasticity; urethral caruncle; resorption of labia minora
  • Vaginal pH >4.5 in untreated postmenopausal patients supports the diagnosis
  • Biopsy is not required
  • No consensus exists on the number or type of symptoms needed for formal diagnosis[10]

Management​

The 2025 AUA/SUFU/AUGS Guideline and the 2020 NAMS Position Statement provide the most current frameworks.[10][3] Treatment is guided by symptom severity and patient preference.

First-line: non-hormonal therapies (mild symptoms)​

  • Vaginal moisturizers (polycarbophil-based, hyaluronic acid) used 1–3 times per week[6][3][11]
  • Vaginal lubricants (water-, silicone-, or oil-based) used during intercourse[3][11]
  • Avoidance of vulvar irritants[6]

Second-line: hormonal therapies (moderate to severe symptoms)​

Low-dose vaginal estrogen is the gold standard and has the most robust evidence base.[1][10][3]

FormulationAgentDoseFrequencyNotes
Estradiol creamEstrace0.1 mg/g; 0.5–2 g/doseDaily × 1–2 wk, then 2–3×/wkHighest systemic absorption of vaginal formulations
Conjugated estrogen creamPremarin0.625 mg/g; 0.5–2 g/doseDaily × 21 d on / 7 d off, or 2×/wkSimilar systemic absorption to estradiol cream
Estradiol hemihydrate insertsVagifem, Yuvafem10 µg/insertDaily × 2 wk, then 2×/wkLower systemic absorption than creams
Estradiol soft gel insertsImvexxy4 µg or 10 µg/insertDaily × 2 wk, then 2×/wkLowest serum E2 among inserts; 4 µg preferred for oncology patients
Estradiol vaginal ringEstring7.5 µg/day (continuous release)Replace every 90 daysLowest and most consistent systemic absorption; preferred for breast cancer survivors

A 2024 systematic review in the Annals of Internal Medicine confirmed that vaginal estrogen, vaginal DHEA (prasterone), oral ospemifene, and vaginal moisturizers may all improve some GSM symptoms in the short term, though long-term comparative effectiveness data remain limited.[12]

Alternative pharmacologic agents (detailed in the pharmacology hub — see cross-references below):

  • Vaginal DHEA (prasterone / Intrarosa): Intracrinology-based mechanism; improves all six FSFI domains including desire and arousal — differentiating it from vaginal estrogen. Serum estrogen remains below postmenopausal levels even in aromatase-inhibitor users.
  • Ospemifene (Osphena): Oral SERM; vaginal agonist and breast antagonist. Strongest off-label signal is OAB/UUI. Take with food. Fluconazole 2.7× AUC interaction.

Adjunctive therapies​

Energy-based therapies (laser and radiofrequency)​

Fractional CO₂ laser and erbium:YAG laser have been studied for GSM. A 2025 systematic review found that CO₂ laser compared with sham showed little to no difference in dyspareunia, dysuria, or quality of life (low certainty of evidence), and similarly showed no significant difference compared with vaginal estrogen.[14] A meta-analysis demonstrated comparable efficacy between laser and vaginal estrogen across multiple outcomes, though heterogeneity was high.[15] The NAMS 2020 position statement concluded there are insufficient placebo-controlled trials to make treatment recommendations for energy-based therapies.[3] These should not yet be considered standard of care.

Special population: breast cancer survivors​

  • Nonhormonal methods are first-line for patients with a history of estrogen-dependent breast cancer.[16]
  • If nonhormonal treatments fail, low-dose vaginal estrogen may be used after shared decision-making, including patients on tamoxifen. For patients on aromatase inhibitors, shared decision-making among patient, gynecologist, and oncologist is recommended.[16]
  • A 2025 meta-analysis of 8 observational studies (>24,000 patients) found no increased risk of breast cancer recurrence (OR 0.48; 95% CI 0.23–0.98), breast cancer mortality (OR 0.60; 95% CI 0.18–1.95), or overall mortality (OR 0.46; 95% CI 0.42–0.49) with vaginal estrogen use.[17]
  • A 2026 review confirmed minimal systemic absorption with low-dose formulations, and noted that the FDA has removed boxed warnings related to breast cancer from vaginal estrogen labels.[18]
  • Rings and suppositories / inserts are preferred over creams for survivors of hormonally sensitive tumors due to lower and more consistent systemic absorption. NCCN Survivorship guidelines endorse this approach.[19]

Cross-references​

  • Vaginal & Topical Estrogen — formulation pharmacology, systemic absorption gradient, safety data by breast cancer status, November 2025 FDA boxed-warning removal.
  • Vaginal DHEA (Prasterone) — intracrinology mechanism, FSFI domain profile, safety in aromatase inhibitor users.
  • Ospemifene — oral SERM; OAB/UUI off-label signal, VTE risk, drug interactions.
  • Recurrent UTI — vaginal estrogen as first-line in postmenopausal patients (AUA/CUA/SUFU 2022 paradigm; Chen 2021 meta RR 0.42 vaginal vs RR 1.11 oral; Tan-Kim 51.9% real-world reduction).
  • Preoperative Hormonal Priming — IMPROVE trial; role of local estrogen before pelvic floor surgery.

References​

1. Faubion SS, Sood R, Kapoor E. "Genitourinary Syndrome of Menopause: Management Strategies for the Clinician." Mayo Clin Proc. 2017;92(12):1842–1849. doi:10.1016/j.mayocp.2017.08.019

2. Crandall CJ, Mehta JM, Manson JE. "Management of Menopausal Symptoms: A Review." JAMA. 2023;329(5):405–420. doi:10.1001/jama.2022.24140

3. North American Menopause Society. "The 2020 Genitourinary Syndrome of Menopause Position Statement of the North American Menopause Society." Menopause. 2020;27(9):976–992. doi:10.1097/GME.0000000000001609

4. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. "Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213." Obstet Gynecol. 2019;134(1):e1–e18. doi:10.1097/AOG.0000000000003324

5. Phillips NA, Bachmann GA. "The Genitourinary Syndrome of Menopause." Menopause. 2021;28(5):579–588. doi:10.1097/GME.0000000000001728

6. Ringel NE, Iglesia C. "Common Benign Chronic Vulvar Disorders." Am Fam Physician. 2020;102(9):550–557.

7. Szymański JK, Słabuszewska-Józwiak A, Jakiel G. "Vaginal Aging — What We Know and What We Do Not Know." Int J Environ Res Public Health. 2021;18(9):4935. doi:10.3390/ijerph18094935

8. Shardell M, Gravitt PE, Burke AE, Ravel J, Brotman RM. "Association of Vaginal Microbiota With Signs and Symptoms of the Genitourinary Syndrome of Menopause Across Reproductive Stages." J Gerontol A Biol Sci Med Sci. 2021;76(9):1542–1550. doi:10.1093/gerona/glab120

9. Qi W, Li H, Wang C, et al. "The Effect of Pathophysiological Changes in the Vaginal Milieu on the Signs and Symptoms of Genitourinary Syndrome of Menopause (GSM)." Menopause. 2020;28(1):102–108. doi:10.1097/GME.0000000000001644

10. Kaufman MR, Ackerman AL, Amin KA, et al. "The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause." J Urol. 2025. doi:10.1097/JU.0000000000004589

11. Chang JG, Lewis MN, Wertz MC. "Managing Menopausal Symptoms: Common Questions and Answers." Am Fam Physician. 2023;108(1):28–39.

12. Danan ER, Sowerby C, Ullman KE, et al. "Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause: A Systematic Review." Ann Intern Med. 2024;177(10):1400–1414. doi:10.7326/ANNALS-24-00610

13. Steinman MA. "Alternative Treatments to Selected Medications in the 2023 American Geriatrics Society Beers Criteria®." J Am Geriatr Soc. 2025;73(9):2657–2677. doi:10.1111/jgs.19500

14. Zerzan NL, Greer N, Ullman KE, et al. "Energy-Based Interventions for Genitourinary Syndrome of Menopause: A Systematic Review of Randomized Controlled Trials and Prospective Observational Studies." Menopause. 2025;32(2):176–183. doi:10.1097/GME.0000000000002465

15. Jang YC, Leung CY, Huang HL. "Comparison of Severity of Genitourinary Syndrome of Menopause Symptoms After Carbon Dioxide Laser vs Vaginal Estrogen Therapy: A Systematic Review and Meta-analysis." JAMA Netw Open. 2022;5(9):e2232563. doi:10.1001/jamanetworkopen.2022.32563

16. American College of Obstetricians and Gynecologists. "Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-Dependent Breast Cancer: Clinical Consensus." Obstet Gynecol. 2021;138(6):950–960. doi:10.1097/AOG.0000000000004601

17. Beste ME, Kaunitz AM, McKinney JA, Sanchez-Ramos L. "Vaginal Estrogen Use in Breast Cancer Survivors: A Systematic Review and Meta-Analysis of Recurrence and Mortality Risks." Am J Obstet Gynecol. 2025;232(3):262–270.e1. doi:10.1016/j.ajog.2024.10.054

18. Mainar LB, Nieto-Pascual L, Bravo EI, et al. "Safety of Vaginal Estrogen in Breast Cancer Survivors: Current Evidence on Systemic Absorption and Oncologic Outcomes." Maturitas. 2026;208:108914. doi:10.1016/j.maturitas.2026.108914

19. National Comprehensive Cancer Network. Survivorship. Updated 2026-04-08. https://www.nccn.org